Aptevo Therapeutics Inc.
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -30.99% | 23.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 53.05% | 22.23% | |||
| Operating Income | -53.05% | -22.23% | |||
| Income Before Tax | 23.09% | -21.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.09% | -21.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.09% | -21.68% | |||
| EBIT | -53.05% | -22.23% | |||
| EBITDA | -51.90% | -22.41% | |||
| EPS Basic | 73.07% | 73.47% | |||
| Normalized Basic EPS | 81.72% | 77.82% | |||
| EPS Diluted | 73.07% | 73.47% | |||
| Normalized Diluted EPS | 81.72% | 77.82% | |||
| Average Basic Shares Outstanding | 320.72% | 448.54% | |||
| Average Diluted Shares Outstanding | 320.72% | 448.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||